News
KYNB
7.20
+1.77%
0.13
Kyntra Bio Price Target Announced at $41.00/Share by Lake Street
Dow Jones · 4d ago
Lake Street Initiates Coverage On Kyntra Bio with Buy Rating, Announces Price Target of $41
Benzinga · 4d ago
Kyntra Bio initiated with a Buy at Lake Street on prostate cancer potential
TipRanks · 4d ago
Kyntra Bio initiated with a Buy at Lake Street
TipRanks · 4d ago
Weekly Report: what happened at KYNB last week (0907-0911)?
Weekly Report · 09/14 09:15
FibroGen Inc trading resumes
TipRanks · 09/10 17:30
Weekly Report: what happened at KYNB last week (0831-0904)?
Weekly Report · 09/07 09:14
Kyntra Bio to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Barchart · 09/02 06:30
Analysts’ Top Healthcare Picks: Kyntra Bio (KYNB), Arrowhead Pharmaceuticals (ARWR)
TipRanks · 09/01 10:40
Kyntra Bio Price Target Maintained With a $43.00/Share by HC Wainwright & Co.
Dow Jones · 09/01 10:36
HC Wainwright & Co. Reiterates Buy on Kyntra Bio, Maintains $43 Price Target
Benzinga · 09/01 10:26
Wall Street Analysts Are Neutral on Top Healthcare Picks
TipRanks · 09/01 01:10
Kyntra Bio Streamlines Financing, Strengthens Balance Sheet
TipRanks · 08/31 21:52
Kyntra Bio cuts max royalty cap to $65M from $125M, pays $42.6M upfront
TipRanks · 08/31 20:45
Kyntra Bio To Reduce The Maximum Aggregate Payments Under Its Royalty Financing Agreement From $125M To $65M; Co. Accelerated Payment Of $42.6M Upfront, Bringing Total Payments Made To Date To $50M; Remaining Payments, Capped At $15M, To Be Paid From 50% Of The Revenue Received From Astellas In The Astellas Territories Excluding Japan
Benzinga · 08/31 20:10
Press Release: Kyntra Bio Continues Balance Sheet Transformation with Material Reduction of Royalty Financing Obligation
Dow Jones · 08/31 20:05
Weekly Report: what happened at KYNB last week (0824-0828)?
Weekly Report · 08/31 09:15
Kyntra Bio Earnings Call Highlights CD46 Oncology Push
TipRanks · 08/25 00:08
Weekly Report: what happened at KYNB last week (0817-0821)?
Weekly Report · 08/24 09:15
Kyntra Bio (KYNB) Q2 2026 Earnings Call Transcript
The Motley Fool · 08/20 21:43
More
Webull provides a variety of real-time KYNB stock news. You can receive the latest news about KYNTRA BIO INC through multiple platforms. This information may help you make smarter investment decisions.
About KYNB
Kyntra Bio, Inc., formerly FibroGen, Inc., is a biopharmaceutical company. The Company is focused on development of novel therapies in oncology and rare disease. The Company continues to evaluate the development plan for the Phase III trial of roxadustat in anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) in the U.S. FG-3246 (also known as FOR46), a first-in-class antibody-drug conjugate (ADC) targeting CD46, is in Phase II development for the treatment of metastatic castration-resistant prostate cancer. This program also includes the development of FG-3180, an associated CD46-targeted PET biomarker. Roxadustat (EVRENZO) is approved in Europe, Japan, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis.